<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574870</url>
  </required_header>
  <id_info>
    <org_study_id>STU 102016-059</org_study_id>
    <nct_id>NCT03574870</nct_id>
  </id_info>
  <brief_title>Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer</brief_title>
  <acronym>FITBIT</acronym>
  <official_title>Feasibility Study of a Wearable Sensor for Acquisition of Biometric Data in Head and Neck Cancer Patients During Locoregional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator will seek to determine the feasibility of wearable biometric sensors to&#xD;
      acquire high resolution biometric data, including heart rate and activity level (i.e. steps)&#xD;
      for patients undergoing radiation therapy and surgery, with or without postoperative&#xD;
      radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active cancer treatment such as surgery, chemotherapy or radiotherapy can cause side effects&#xD;
      or toxicities, which, if untreated, can lead to poorer quality of life, decreased patient&#xD;
      well-being, and worse clinical outcomes. Routine monitoring of patients while under active&#xD;
      treatment can entail the routine practice of clinic visits at regular intervals with the&#xD;
      acquisition of vital signs, routine laboratory testing, patient-reported outcome surveys, and&#xD;
      face-to-face interaction with their physician.&#xD;
&#xD;
      In recent years, the availability of commercially-available wearable fitness sensors has&#xD;
      allowed end-users to monitor their fitness progress and activity levels. These devices depend&#xD;
      on small sensors that can collect minute-to-minute data on heart rate and activity level that&#xD;
      may be transmitted to a smartphone or computer. Through this system, users can easily track&#xD;
      and monitor their fitness progress.&#xD;
&#xD;
      In this trial, the investigator will seek to determine the feasibility of wearable biometric&#xD;
      sensors to acquire high resolution biometric data, including heart rate and activity level&#xD;
      (i.e. steps) for patients undergoing radiation therapy and surgery, with or without&#xD;
      postoperative radiotherapy. The investigator believe that changes in heart rate may predict&#xD;
      for increasing pain, dehydration, and stress in general. Moreover, changes in daily step&#xD;
      count are a surrogate for performance status on treatment, and the investigator will perform&#xD;
      a series of preliminary analyses to assess whether there is validity to this hypothesis. The&#xD;
      investigator hope to use biometric monitoring to identify patients at risk for adverse&#xD;
      outcomes, with the ultimate goal of intervening before these outcomes occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who could wear the device more than 90% of the time, of 23 hours a day, daily</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the feasibility of using a commercially-available wearable sensor to obtain biometric data for patients undergoing head and neck locoregional therapy throughout the duration of radiation treatment (cohorts A, B-RT) and throughout post-surgical recovery with or without adjuvant radiotherapy (cohort B)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily data acquisition rate</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of successful data acquisition events as well as a retention rate of all enrolled participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in daily steps taken</measure>
    <time_frame>3 months</time_frame>
    <description>Data will be collected using the Fitbit device and aggregated using the Fitabase platform throughout the duration of radiation treatment (cohorts A, B-RT) and throughout post-surgical recovery with or without adjuvant radiotherapy (cohort B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>3 months</time_frame>
    <description>Data will be collected using the Fitbit device and aggregated using the Fitabase platform throughout the duration of radiation treatment (cohorts A, B-RT) and throughout post-surgical recovery with or without adjuvant radiotherapy (cohort B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep habits</measure>
    <time_frame>3 months</time_frame>
    <description>Data will be collected using the Fitbit device and aggregated using the Fitabase platform throughout the duration of radiation treatment (cohorts A, B-RT) and throughout post-surgical recovery with or without adjuvant radiotherapy (cohort B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of intravenous fluids</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and complications and interventions by the volume of intravenous fluids required for patients undergoing radiation treatment (cohorts A, B-RT) and surgical recovery +/-adjuvant radiotherapy (cohort B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of inpatient hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and complications and interventions days of inpatient hospitalization required for patients undergoing radiation treatment (cohorts A, B-RT) and surgical recovery +/-adjuvant radiotherapy (cohort B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain level</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and complications and interventions by changes in pain level of patients undergoing radiation treatment (cohorts A, B-RT) and surgical recovery +/-adjuvant radiotherapy (cohort B).&#xD;
Pain assessments are based on self-report. Pain scale from 0 no pain, 1-3 minor pain, 4-6 moderate pain to 7-10 severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency department visits.</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and complications and interventions number of emergency department visits required for patients undergoing radiation treatment (cohorts A, B-RT) and surgical recovery +/-adjuvant radiotherapy (cohort B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization of pain medication</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and complications and interventions utilization of pain medication required for patients undergoing radiation treatment (cohorts A, B-RT) and surgical recovery +/-adjuvant radiotherapy (cohort B).&#xD;
Medication Quantification Scale (MQS) Version III will be used to determine drug detriment weight and dosage level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical and mental well-being</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and patient-reported outcomes in regards to physical and mental well-being using the Functional Assessment of Cancer Therapy - General (FACT-G) Health Survey at each weekly scheduled visit to monitor for acute changes in their condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>3 months</time_frame>
    <description>To analyze associations between biometric parameters and patient-reported outcomes in regards to sleep quality using the Pittsburgh Sleep Quality Index (PSQI)&#xD;
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Chemoraditherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with head and neck cancer require chemo and radiation therapy (Cohort A):&#xD;
A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary surgery w/o radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with head and neck cancer require primary surgery alone (Cohort B-SA)&#xD;
A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery&#xD;
Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)&#xD;
A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>wearable sensor</intervention_name>
    <description>A commercially-available wearable fitness sensor</description>
    <arm_group_label>Chemoraditherapy</arm_group_label>
    <arm_group_label>Primary surgery w/o radiotherapy</arm_group_label>
    <other_name>FITBIT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy-proven malignancy requiring chemoradiation therapy to the head and neck, OR&#xD;
             primary surgery to the head and neck, with or without adjuvant radiotherapy or&#xD;
             chemoradiotherapy.&#xD;
&#xD;
          2. Age â‰¥ 18 years.&#xD;
&#xD;
          3. Performance status ECOG 0-2&#xD;
&#xD;
             Per typical radiotherapy policy, women of child-bearing potential and men must agree&#xD;
             to use adequate contraception (hormonal or barrier method of birth control;&#xD;
             abstinence) prior to study entry.&#xD;
&#xD;
             3.1 A female of child-bearing potential is any woman (regardless of sexual&#xD;
             orientation, having undergone a tubal ligation, or remaining celibate by choice) who&#xD;
             meets the following criteria:&#xD;
&#xD;
               -  Has not undergone a hysterectomy or bilateral oophorectomy; or&#xD;
&#xD;
               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,&#xD;
                  has had menses at any time in the preceding 12 consecutive months).&#xD;
&#xD;
          4. Concurrent chemotherapy is required for definitive radiotherapy patients&#xD;
&#xD;
          5. Hypofractionated or stereotactic body radiation therapy is not permitted&#xD;
&#xD;
          6. Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
          7. Willingness to download the Fitbit App to a personal mobile device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          2. Subjects must not be pregnant or nursing due to the potential for congenital&#xD;
             abnormalities and the potential of this regimen to harm nursing infants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Sher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

